Changing epidemiology of candidaemia in Australia

Belinda Chapman, Monica Slavin, Debbie Marriott, Catriona L Halliday, Sarah E Kidd, Ian H Arthur, Narin Bak, Christopher H Heath, Karina Kennedy, C. Orla Morrissey, Tania C Sorrell, Sebastian Van Hal, Caitlin Keighley, Emma Goeman, Neil Underwood, Krispin Hajkowicz, Ann Hofmeyr, Michael J. Leung, Nenad Macesic, Jeannie Botes & 15 others Christopher Blyth, Louise A Cooley, C. Robert George, Pankaja Kalukottege, Alison Kesson, Brendan Joseph McMullan, Robert W Baird, Jennifer Robson, Tony M. Korman, Stella Pendle, Kerry Weeks, Eunice Liu, Elaine Cheong, Sharon Chen, on behalf of the Australian and New Zealand Mycoses Interest Group

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.

Original languageEnglish
Pages (from-to)1103-1108
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume72
Issue number4
DOIs
Publication statusPublished - 1 Apr 2017

Cite this

Chapman, B., Slavin, M., Marriott, D., Halliday, C. L., Kidd, S. E., Arthur, I. H., ... on behalf of the Australian and New Zealand Mycoses Interest Group (2017). Changing epidemiology of candidaemia in Australia. Journal of Antimicrobial Chemotherapy, 72(4), 1103-1108. https://doi.org/10.1093/jac/dkw422
Chapman, Belinda ; Slavin, Monica ; Marriott, Debbie ; Halliday, Catriona L ; Kidd, Sarah E ; Arthur, Ian H ; Bak, Narin ; Heath, Christopher H ; Kennedy, Karina ; Morrissey, C. Orla ; Sorrell, Tania C ; Van Hal, Sebastian ; Keighley, Caitlin ; Goeman, Emma ; Underwood, Neil ; Hajkowicz, Krispin ; Hofmeyr, Ann ; Leung, Michael J. ; Macesic, Nenad ; Botes, Jeannie ; Blyth, Christopher ; Cooley, Louise A ; George, C. Robert ; Kalukottege, Pankaja ; Kesson, Alison ; McMullan, Brendan Joseph ; Baird, Robert W ; Robson, Jennifer ; Korman, Tony M. ; Pendle, Stella ; Weeks, Kerry ; Liu, Eunice ; Cheong, Elaine ; Chen, Sharon ; on behalf of the Australian and New Zealand Mycoses Interest Group. / Changing epidemiology of candidaemia in Australia. In: Journal of Antimicrobial Chemotherapy. 2017 ; Vol. 72, No. 4. pp. 1103-1108.
@article{3787b931ea3b48c1afd7ed7a8cb27b18,
title = "Changing epidemiology of candidaemia in Australia",
abstract = "Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56{\%} of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4{\%}) followed by Candida glabrata complex (26.7{\%}) and Candida parapsilosis complex (16.5{\%}). Uncommon Candida species comprised 25 (5{\%}) isolates. Overall, C. albicans (>99{\%}) and C. parapsilosis (98.8{\%}) were fluconazole susceptible. However, 16.7{\%} (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8{\%} were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7{\%} versus 16{\%} in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7{\%} of isolates) amongst C. tropicalis may be emerging.",
author = "Belinda Chapman and Monica Slavin and Debbie Marriott and Halliday, {Catriona L} and Kidd, {Sarah E} and Arthur, {Ian H} and Narin Bak and Heath, {Christopher H} and Karina Kennedy and Morrissey, {C. Orla} and Sorrell, {Tania C} and {Van Hal}, Sebastian and Caitlin Keighley and Emma Goeman and Neil Underwood and Krispin Hajkowicz and Ann Hofmeyr and Leung, {Michael J.} and Nenad Macesic and Jeannie Botes and Christopher Blyth and Cooley, {Louise A} and George, {C. Robert} and Pankaja Kalukottege and Alison Kesson and McMullan, {Brendan Joseph} and Baird, {Robert W} and Jennifer Robson and Korman, {Tony M.} and Stella Pendle and Kerry Weeks and Eunice Liu and Elaine Cheong and Sharon Chen and {on behalf of the Australian and New Zealand Mycoses Interest Group}",
year = "2017",
month = "4",
day = "1",
doi = "10.1093/jac/dkw422",
language = "English",
volume = "72",
pages = "1103--1108",
journal = "Journal of Antimicrobial Chemotherapy",
issn = "0305-7453",
publisher = "Oxford University Press",
number = "4",

}

Chapman, B, Slavin, M, Marriott, D, Halliday, CL, Kidd, SE, Arthur, IH, Bak, N, Heath, CH, Kennedy, K, Morrissey, CO, Sorrell, TC, Van Hal, S, Keighley, C, Goeman, E, Underwood, N, Hajkowicz, K, Hofmeyr, A, Leung, MJ, Macesic, N, Botes, J, Blyth, C, Cooley, LA, George, CR, Kalukottege, P, Kesson, A, McMullan, BJ, Baird, RW, Robson, J, Korman, TM, Pendle, S, Weeks, K, Liu, E, Cheong, E, Chen, S & on behalf of the Australian and New Zealand Mycoses Interest Group 2017, 'Changing epidemiology of candidaemia in Australia' Journal of Antimicrobial Chemotherapy, vol. 72, no. 4, pp. 1103-1108. https://doi.org/10.1093/jac/dkw422

Changing epidemiology of candidaemia in Australia. / Chapman, Belinda; Slavin, Monica; Marriott, Debbie; Halliday, Catriona L; Kidd, Sarah E; Arthur, Ian H; Bak, Narin; Heath, Christopher H; Kennedy, Karina; Morrissey, C. Orla; Sorrell, Tania C; Van Hal, Sebastian; Keighley, Caitlin; Goeman, Emma; Underwood, Neil; Hajkowicz, Krispin; Hofmeyr, Ann; Leung, Michael J.; Macesic, Nenad; Botes, Jeannie; Blyth, Christopher; Cooley, Louise A; George, C. Robert; Kalukottege, Pankaja; Kesson, Alison; McMullan, Brendan Joseph; Baird, Robert W; Robson, Jennifer ; Korman, Tony M.; Pendle, Stella; Weeks, Kerry; Liu, Eunice; Cheong, Elaine; Chen, Sharon; on behalf of the Australian and New Zealand Mycoses Interest Group.

In: Journal of Antimicrobial Chemotherapy, Vol. 72, No. 4, 01.04.2017, p. 1103-1108.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Changing epidemiology of candidaemia in Australia

AU - Chapman, Belinda

AU - Slavin, Monica

AU - Marriott, Debbie

AU - Halliday, Catriona L

AU - Kidd, Sarah E

AU - Arthur, Ian H

AU - Bak, Narin

AU - Heath, Christopher H

AU - Kennedy, Karina

AU - Morrissey, C. Orla

AU - Sorrell, Tania C

AU - Van Hal, Sebastian

AU - Keighley, Caitlin

AU - Goeman, Emma

AU - Underwood, Neil

AU - Hajkowicz, Krispin

AU - Hofmeyr, Ann

AU - Leung, Michael J.

AU - Macesic, Nenad

AU - Botes, Jeannie

AU - Blyth, Christopher

AU - Cooley, Louise A

AU - George, C. Robert

AU - Kalukottege, Pankaja

AU - Kesson, Alison

AU - McMullan, Brendan Joseph

AU - Baird, Robert W

AU - Robson, Jennifer

AU - Korman, Tony M.

AU - Pendle, Stella

AU - Weeks, Kerry

AU - Liu, Eunice

AU - Cheong, Elaine

AU - Chen, Sharon

AU - on behalf of the Australian and New Zealand Mycoses Interest Group

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.

AB - Objectives: Knowledge of contemporary epidemiology of candidaemia is essential.We aimed to identify changes since 2004 in incidence, species epidemiology and antifungal susceptibilities of Candida spp. causing candidaemia in Australia. Methods: These data were collected from nationwide active laboratory-based surveillance for candidaemia over 1 year (within 2014-2015). Isolate identification was by MALDI-TOF MS supplemented by DNA sequencing. Antifungal susceptibility testing was performed using Sensititre YeastOneTM. Results: A total of 527 candidaemia episodes (yielding 548 isolates) were evaluable. The mean annual incidence was 2.41/105 population. The median patient agewas 63 years (56% of cases occurred in males). Of 498 isolates with confirmed species identity, Candida albicans was the most common (44.4%) followed by Candida glabrata complex (26.7%) and Candida parapsilosis complex (16.5%). Uncommon Candida species comprised 25 (5%) isolates. Overall, C. albicans (>99%) and C. parapsilosis (98.8%) were fluconazole susceptible. However, 16.7% (4 of 24) of Candida tropicalis were fluconazole- and voriconazole-resistant and were non-WT to posaconazole. Of C. glabrata isolates, 6.8% were resistant/non-WT to azoles; only one isolate was classed as resistant to caspofungin (MIC of 0.5 mg/L) by CLSI criteria, but was micafungin and anidulafungin susceptible. There was no azole/ echinocandin co-resistance. Conclusions:We report an almost 1.7-fold proportional increase in C. glabrata candidaemia (26.7% versus 16% in 2004) in Australia. Antifungal resistance was generally uncommon, but azole resistance (16.7% of isolates) amongst C. tropicalis may be emerging.

UR - http://www.scopus.com/inward/record.url?scp=85018362721&partnerID=8YFLogxK

U2 - 10.1093/jac/dkw422

DO - 10.1093/jac/dkw422

M3 - Article

VL - 72

SP - 1103

EP - 1108

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

SN - 0305-7453

IS - 4

ER -

Chapman B, Slavin M, Marriott D, Halliday CL, Kidd SE, Arthur IH et al. Changing epidemiology of candidaemia in Australia. Journal of Antimicrobial Chemotherapy. 2017 Apr 1;72(4):1103-1108. https://doi.org/10.1093/jac/dkw422